The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

• Hoofdauteurs: Shen Lin (Auteur), Yaping Huang (Auteur), Liangliang Dong (Auteur), Meiyue Li (Auteur), Yahong Wang (Auteur), Dian Gu (Auteur), Wei Wu (Auteur), Dongni Nian (Auteur), Shaohong Luo (Auteur), Xiaoting Huang (Auteur), Xiongwei Xu (Auteur), Xiuhua Weng (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background: Life expectancy for patients with malignant tumors has been significantly improved since the presence of the programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) inhibitors in 2014, but they impose heavy financial burdens for patients, the healthcare system...